Guillain-Barré Syndrome: Treatment Recommendations
Intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days is the recommended first-line treatment for Guillain-Barré syndrome in patients unable to walk unaided within 2 weeks of symptom onset. 1, 2
Primary Treatment Options
Two equally effective treatments exist for GBS, but IVIg is preferred over plasma exchange for practical reasons:
Intravenous Immunoglobulin (First Choice)
- Dose: 0.4 g/kg body weight daily for 5 consecutive days (total 2 g/kg)
- Timing: Initiate within 2 weeks of weakness onset if patient cannot walk unaided
- Advantages: Easier to administer, more widely available, better tolerated than plasma exchange 1
Plasma Exchange (Alternative)
- Dose: 200-250 ml plasma/kg body weight over 5 sessions (12-15 L total over 1-2 weeks)
- Timing: Within 4 weeks of weakness onset if unable to walk unaided
- Limitations: Requires specialized centers, trained personnel, higher discontinuation rates due to adverse events, more discomfort especially in children 1, 2, 3
Both treatments are equally effective in hastening recovery and improving outcomes, but IVIg is usually the treatment of choice due to ease of administration. 1
What NOT to Do
Avoid These Interventions:
- Corticosteroids alone: Eight randomized trials showed no benefit; oral corticosteroids actually worsened outcomes 1, 2
- Sequential therapy (PE followed by IVIg): No more effective than either treatment alone 1, 3
- Second IVIg course in poor prognosis patients: Not recommended based on recent evidence 2
Special Populations
Children
- Use standard adult IVIg regimen: 0.4 g/kg daily for 5 days
- Avoid 2-day regimens (2 g/kg over 2 days): Associated with higher treatment-related fluctuation rates (5/23 vs 0/23 children) 1
- IVIg preferred over plasma exchange due to technical challenges and higher complication rates with PE in children 1
Pregnant Women
- Both IVIg and plasma exchange are safe
- IVIg preferred due to fewer monitoring requirements 1
Miller Fisher Syndrome (MFS)
- Treatment generally not recommended for pure MFS
- Most recover completely within 6 months without treatment
- Monitor closely: Subgroup can develop limb weakness, bulbar palsy, or respiratory failure requiring treatment 1
Critical Monitoring Requirements
Respiratory Function (Priority)
Up to 22% require mechanical ventilation within the first week. Monitor for:
- Breathlessness at rest or during talking
- Inability to count to 15 in one breath
- Use of accessory respiratory muscles
- "20/30/40 rule": Risk of respiratory failure if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1
Use EGRIS Score
Calculate Erasmus GBS Respiratory Insufficiency Score on admission to predict need for mechanical ventilation within 1 week 1
ICU Admission Criteria
- Evolving respiratory distress with imminent insufficiency
- Severe autonomic dysfunction (arrhythmias, blood pressure instability)
- Severe swallowing dysfunction or diminished cough reflex
- Rapid progression of weakness 1
Managing Treatment Failures
Insufficient Response (40% of patients)
- Disease progression within 4 weeks despite treatment does not prove treatment failure
- No evidence supports repeat treatment or switching therapies, though commonly practiced
- Clinical trial investigating second IVIg dose is ongoing 1
Treatment-Related Fluctuations (6-10% of patients)
- Defined as progression within 2 months after initial improvement/stabilization
- Common practice: Repeat full course of IVIg or plasma exchange
- Evidence: Lacking, but rationale is that treatment effect wore off while inflammation continues 1
Acute-Onset CIDP (~5% of patients)
- Consider if ≥3 treatment-related fluctuations OR deterioration ≥8 weeks after onset
- Requires change in diagnosis and management approach 1, 2
Prognostic Assessment
Use modified Erasmus GBS Outcome Score (mEGOS) on admission to predict functional outcome and guide treatment intensity 1, 2, 4
Recovery continues beyond 3 years in many patients; recurrence is rare (2-5%) 1
Common Pitfalls
- Don't wait for CSF or electrophysiology results to start treatment if clinical diagnosis is clear and patient cannot walk unaided
- Don't assume dyspnea will precede respiratory failure - monitor vital capacity and respiratory pressures routinely 1
- Don't use 2-day IVIg regimens in children despite convenience 1
- Don't dismiss atypical presentations in young children (irritability, refusal to bear weight, poorly localized pain) 1